Trial Profile

A First-in-Human Phase 1 multicenter, open-label Clinical Trial of ITI-5000 in patients with Stage II–III Triple-Negative Breast Cancer (TNBC) as monotherapy and in combination with pembrolizumab (Keytruda)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 18 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Feb 2026 New trial record
20 Jan 2026 According to an Immunomic Therapeutics media release, the USFDA has cleared the IND application for this trial, and the company expects to begin patient enrollment in Q2 2026 in up to eight U.S. clinical sites.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com